Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 13Neoplasm Metastasis 12Prostatic Neoplasms 9Neoplasms 7Glioblastoma 7Kidney Neoplasms 6Brain Neoplasms 6Sarcoma 5Carcinoma, Hepatocellular 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Glioma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Advanced Cancer 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Oligodendroglioma 3Multiple Myeloma 3Lymphoma, Mantle-Cell 3Liver Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2

Interventions

Cyclophosphamide 10fludarabine 5Radiotherapy 5Doxorubicin 5Gemcitabine 3sargramostim 2fludarabine phosphate 2aldesleukin 2Sunitinib 2Radiation Dose Hypofractionation 2Nivolumab 2Leukapheresis 2Ifosfamide 2Docetaxel 2Decitabine 2Dacarbazine 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trofosfamide 1tremelimumab 1temsirolimus 1sotigalimab 1ribociclib 1poly ICLC 1pembrolizumab 1pegfilgrastim 1pazopanib 1pasireotide 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Synovial × temsirolimus × Clear all
NCT00949325 2019-03-11

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
24 enrolled 14 charts
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡